Apexigen, Inc. (APGN) Research

Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.

Market snapshot

Symbol
APGN
Price
$0.39
Day change
+8.48%
Market cap
$9.6M
P/E ratio
-0.24x
52-week range
0.331-8.28
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Allena Pharmaceuticals, Inc. (ALNA)
  • Applied Molecular Transport Inc. (AMTI)
  • Axcella Health Inc. (AXLA)
  • Boston Therapeutics, Inc. (BTHE)
  • Channel Therapeutics Corporation (CHRO)
  • IMV Inc. (IMVIF)
  • Korro Bio, Inc. (KRRO)
  • ObsEva S.A. (OBSV)

Recent insider activity

  • Zabrowksi Dan — D-Return (100000 shares) on 2023-08-23
  • Wertheimer Samuel P — D-Return (12383 shares) on 2023-08-23
  • Wertheimer Samuel P — D-Return (1845 shares) on 2023-08-23
  • Wertheimer Samuel P — D-Return (146383 shares) on 2023-08-23
  • Wertheimer Samuel P — D-Return (100000 shares) on 2023-08-23

Open Apexigen, Inc. (APGN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.